AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32164673
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy (trimethoprim 160 mg/sulfamethoxazole 800 mg twice a day plus folic acid 5 mg daily or doxycycline 100 mg once daily if body weight is < 50 kg or 100 mg twice daily if ≥50 kg)
Trial: 34982157
Drug: Weekly midturbinate
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly midturbinate swabbing
Trial: 34698931
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g TXA i.v. preoperatively
Trial: 34133089
Drug: Vortioxetine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (5 mg)
Trial: 34133089
Drug: Vortioxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (10 mg)
Trial: 34133089
Drug: Vortioxetine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (15 mg)
Trial: 34133089
Drug: Vortioxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (20 mg)
Trial: 32936480
Drug: Tisseel plus
RxNorm normalized name: Tisseel
DrugBank: Human thrombin (DB11571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisseel plus PEP (TEPEP) patch
Trial: 32936480
Drug: Tisseel patch
RxNorm normalized name: Tisseel
DrugBank: Human thrombin (DB11571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisseel patch alone
Trial: 36045119
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral hydrocortisone
Trial: 35150597
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy (BQT)
Trial: 35150597
Drug: Rabeprazole plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole plus amoxicillin dual therapy (RADT)
Trial: 33283636
Drug: Management of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management of local intravascular coagulopathy (LIC) with low‐molecular‐weight heparin (LMWH) and other anticoagulants
Trial: 33283636
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment options including compression, sclerotherapy, laser therapy, cryoablation, and surgery
Trial: 33283636
Drug: Targeted molecular
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Targeted molecular therapies acting on the PI3Kinase/AKT/mTOR pathway
Trial: 34336630
Drug: 0.5 µ/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group L)
Trial: 34336630
Drug: 1 µ/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group M)
Trial: 34336630
Drug: 1.5 µ/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group H)
Trial: 33715871
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate (UPA) 10 mg orally once a day for 12 weeks
Trial: 33715871
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate (LEU) 1.88 mg or 3.75 mg subcutaneously at weeks 0, 4, and 8
Trial: 35477635
Drug: REL-1017 25
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REL-1017 25 mg (75 mg loading dose on day 1)
Trial: 35477635
Drug: REL-1017 50
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REL-1017 50 mg (100 mg loading dose on day 1)
Trial: 36438822
Drug: Kampo group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kampo group receiving mixed extract granules of kakkonto (2.5 g) and shosaikotokakikyosekko (2.5 g) three times a day for 14 days in addition to conventional treatment
Trial: 36438822
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving conventional treatment for symptom relief such as antipyretics and antitussives
Trial: 34127045
Drug: Ca-polyP in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca-polyP in combination with biphasic calcium phosphate (BCP)
Trial: 34850164
Drug: eGo-style ENDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGo-style ENDS with 36 mg/ml nicotine liquid
Trial: 34850164
Drug: eGo-style ENDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGo-style ENDS with 0 mg/ml nicotine liquid
Trial: 34850164
Drug: eGo-style ENDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGo-style ENDS with 8 mg/ml nicotine liquid
Trial: 34969263
Drug: Metal Telescopic
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metal Telescopic Dilator (MTD) using sequential MTD (9-30F)
Trial: 35470551
Drug: Amphetamine (AMPH)
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (AMPH) 30 mg
Trial: 39463173
Drug: Desvenlafaxine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (50 mg/day)
Trial: 35937386
Drug: Microneedle injection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedle injection of MEBO combined with blood transfusion
Trial: 35937386
Drug: Moist exposed
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moist exposed burn ointment (MEBO) combined with blood transfusion
Trial: 35937386
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment external application
Trial: 34167872
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus standard of care
Trial: 32788001
Drug: Irradiated teeth
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiated teeth (exposed to radiation at a dose fraction of two Gy for five consecutive days until reaching a total dose of 60 Gy)
Trial: 33792451
Drug: Noninvasive ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive ventilation (NIV) prescribed to patients with SVC decline; reasons for prescription.
Trial: 35605013
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg daily oral tamoxifen
Trial: 35605013
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg daily oral tamoxifen
Trial: 35343332
Drug: Contrast with
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast with compression (CwC) therapy
Trial: 32914483
Drug: Black barberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black barberry extract (1,000 mg, two capsules daily for 12 weeks)
Trial: 32914483
Drug: Maltodextrin placebo
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin placebo (two capsules daily for 12 weeks)
Trial: 35895150
Drug: Khanya intervention
RxNorm normalized name: Khaya senegalensis bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Khanya intervention (cognitive-behavioral therapy-based)
Trial: 36302965
Drug: Oxytocin nasal
RxNorm normalized name: oxytocin Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin nasal spray (16 IU, administered morning and night for 12 weeks)
Trial: 36302965
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray (administered morning and night for 12 weeks)
Trial: 32052341
Drug: Aflibercept with
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept with chemotherapy
Trial: 36121843
Drug: Fibersol-2 low
RxNorm normalized name: Dianeal Low Calcium 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibersol-2 low dose (2.5g)
Trial: 36121843
Drug: Fibersol-2 high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibersol-2 high dose (5g)
Trial: 38909229
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic gel
Trial: 36336989
Drug: Hydroxypropyl chitosan-based
RxNorm normalized name: hydroxypropyl chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxypropyl chitosan-based 80 mg/g ciclopirox nail lacquer
Trial: 35946753
Drug: Placebo protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo protocol (250 mL of water)
Trial: 33629490
Drug: Haemoglobin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoglobin levels of 70–89 g/l at 6+0–13+6 weeks
Trial: 33629490
Drug: Haemoglobin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemoglobin levels of 110–129 g/l at 6+0–13+6 weeks
Trial: 35168560
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by 6 months of oral uracil and tegafur plus leucovorin (UFT/LV)
Trial: 33922546
Drug: Sodium glucose
RxNorm normalized name: Sodium glucose cotransporter subtype 2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium glucose cotransporter 2 inhibitors (SGLT2i)
Trial: 35715681
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Macrogol-based solution the day prior to examination (Regimen A)
Trial: 35715681
Drug: Fractionated dose
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated dose of Macrogol-based solution 2 days before examination (Regimen B)
Trial: 35715681
Drug: Fractionated dose
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated dose of Macrogol-based solution 3 days before examination (Regimen C)
Trial: 37668277
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo infusion
Trial: 39075484
Drug: Aspirin cessation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin cessation
Trial: 33170486
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) treatment
Trial: 34960061
Drug: LC-Plasma tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC-Plasma tablets (approximately 100 billion cells/day) for 8 weeks
Trial: 32316993
Drug: Onsite molecular
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Onsite molecular testing using GeneXpert Edge, process redesign to facilitate same-day TB diagnosis and treatment, and performance feedback
Trial: 34995992
Drug: Escitalopram monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram monotherapy for 8-12 weeks
Trial: 35212574
Drug: Cytoreductive nephrectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive nephrectomy (CN) with systemic therapy
Trial: 34107013
Drug: Upadacitinib 45
RxNorm normalized name: upadacitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 45 mg once daily (QD)
Trial: 33021715
Drug: Antihypertensive drug
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drug and lifestyle intervention therapies
Trial: 33021715
Drug: Standard antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antihypertensive drug intervention therapy
Trial: 32063109
Drug: N-acetylcysteine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (two 600 mg tablets)
Trial: 33632752
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive ablative therapy to prostate±pelvic lymph node dissection (PLND)
Trial: 33632752
Drug: All arms
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All arms will receive standard systemic therapy with ADT±upfront systemic chemotherapy or androgen receptor agents.
Trial: 33526484
Drug: Oxfendazole (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxfendazole (0.5 to 60 mg/kg)
Trial: 33486643
Drug: Risk prediction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk prediction score based on 7 factors (stoma creation, Peritoneal Cancer Index score ≥15, hyponatremia, in-hospital major complication, preoperative chemotherapy, anemia, discharge to nursing home)
Trial: 32152693
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion with indwelling needles
Trial: 32152693
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion with steel needles
Trial: 35337021
Drug: Baseline viral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline viral load <2 mill IU/mL
Trial: 36243227
Drug: Direct consultations
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct consultations with a medical physicist during treatment simulation and before the first treatment.
Trial: 32324840
Drug: Individualized homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathic treatment (IHT) with homeopathic remedies at 30C (10-60) and 200C (10-400) dilutions
Trial: 33662894
Drug: Cenobamate 100
RxNorm normalized name: cenobamate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate 100 mg once daily
Trial: 33662894
Drug: Cenobamate 200
RxNorm normalized name: cenobamate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate 200 mg once daily
Trial: 33662894
Drug: Cenobamate 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate 400 mg once daily
Trial: 32040868
Drug: Doxepin cream
RxNorm normalized name: doxepin Topical Cream
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin cream (5%) for 7 days
Trial: 32040868
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream for 7 days
Trial: 33684953
Drug: 1 tablet
RxNorm normalized name: Ovral-21 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of metformin SR 1000 mg and 1 tablet of TQ 50 mg once daily (T1)
Trial: 33684953
Drug: 1 tablet
RxNorm normalized name: Ovral-21 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of metformin SR 1000 mg and 2 tablets of TQ 50 mg once daily (T2)
Trial: 33684953
Drug: 1 tablet
RxNorm normalized name: Ovral-21 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of metformin SR 1000 mg only (R)
Trial: 32027810
Drug: Ultra-low dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dosage of rituximab (200 mg single infusion)
Trial: 35333885
Drug: Vitamin D3-fortified
RxNorm normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3-fortified fruit juices containing 4000 IU (100 mcg) daily for 8 weeks
Trial: 35333885
Drug: Placebo-fruit juices
RxNorm normalized name: Morinda citrifolia fruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-fruit juices daily for 8 weeks
Trial: 36288843
Drug: Dry needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry needling (DN) intervention, performed thrice a week for 2 weeks, in addition to conventional treatment
Trial: 36288843
Drug: Conventional treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment, performed once a day for 40 min, five times a week for 2 weeks
Trial: 33333459
Drug: Clinical decision
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical decision support alert for carbohydrate-containing medication orders
Trial: 35435565
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning models for predicting resistance to somatostatin receptor ligands (SRL)
Trial: 33830998
Drug: 850 mg
RxNorm normalized name: bran 850 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 850 mg metformin three times daily
Trial: 35750726
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education (Group I)
Trial: 34845600
Drug: Lactocare® (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactocare® (two times daily for 12 weeks)
Trial: 34845600
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two times daily for 12 weeks)
Trial: 33179818
Drug: Pump therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pump therapy with continuous glucose monitoring offering low glucose suspend (LGS)
Trial: 34843843
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO) treatment with 30 pre- and 10 postoperative exposures at 243 kPa for 90 min each
Trial: 32920607
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide gel (Opalescence, Ultradent Products) (2 h/day, for 14 days)
Trial: 32920607
Drug: 40% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% hydrogen peroxide gel (Opalescence Boost, Ultradent Products) (three bleaching sessions, once a week, 45 min/session)
Trial: 36331921
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo treatment
Trial: 35461522
Drug: All chimeric
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All chimeric vaccines
Trial: 36494245
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (Group T)
Trial: 32087032
Drug: Oral bacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bacterial lysate (heat-killed Escherichia coli and Enterococcus faecalis)
Trial: 36156542
Drug: Glucosamine and
RxNorm normalized name: Glucosamine and Chondroitin Complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine and chondroitin sulfate supplementation for 4 weeks in addition to manual therapy and resistance exercise training.
Trial: 36156542
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and resistance exercise training.
Trial: 32306797
Drug: Triple therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy: aspirin+prasugrel/ticagrelor+vorapaxar
Trial: 32306797
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (drop aspirin): prasugrel/ticagrelor+vorapaxar
Trial: 32306797
Drug: DAPT: aspirin+prasugrel/ticagrelor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT: aspirin+prasugrel/ticagrelor
Trial: 34478926
Drug: Atosiban (6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (6.75 mg IV 30 min before embryo transfer, followed by 18 mg/h for 1 h, then 6 mg/h for 2 h)
Trial: 32870042
Drug: Autologous Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Protein Solution (APS) injection
Trial: 33184453
Drug: Iodine status
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine status (UI/Cr <150 µg/g)
Trial: 37753718
Drug: Etripamil nasal
RxNorm normalized name: etripamil
DrugBank: Etripamil (DB12605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etripamil nasal spray
Trial: 35551053
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) using a low-level GaAlAs diode laser (continuous wave of 810 nm wavelength, power of 200 mW, energy density of 12–14 J/cm2) for 12 sessions (2 times/week for 6 weeks)
Trial: 33641621
Drug: Protect Your
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protect Your Family intervention administered by lay healthcare workers
Trial: 32380509
Drug: Acid-suppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-suppressive therapy + feeding bundle
Trial: 32380509
Drug: Acid-suppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-suppressive therapy only (conventional)
Trial: 33064895
Drug: New metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New metformin users with depression
Trial: 33064895
Drug: New metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New metformin users without depression (controls)
Trial: 35732505
Drug: Superficial Acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial Acupuncture (SA) group, same sessions and treatment frequency as TA, avoiding deqi sensation.
Trial: 36442467
Drug: Early feeding
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early feeding group (1 day of trophic feeding at 20-24 mL/kg/day)